Citadel Advisors
BVS icon

Citadel Advisors’s Bioventus BVS Stock Holding History

Citadel Advisors’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$607K Buy
66,500
+17,400
+35% +$146K ﹤0.01% 8821
2025
Q4 		$365K Buy
49,100
+24,400
+99% +$175K ﹤0.01% 9729
2025
Q3 		$165K Sell
24,700
-13,200
-35% -$91.6K ﹤0.01% 11455
2025
Q2 		$251K Buy
37,900
+20,300
+115% +$144K ﹤0.01% 10202
2025
Q1 		$161K Buy
17,600
+3,400
+24% +$34K ﹤0.01% 10761
2024
Q4 		$149K Sell
14,200
-1,100
-7% -$13K ﹤0.01% 10894
2024
Q3 		$183K Buy
15,300
+8,500
+125% +$73.5K ﹤0.01% 10288
2024
Q2 		$39.1K Buy
6,800
+400
+6% +$2.19K ﹤0.01% 12016
2024
Q1 		$33.3K Sell
6,400
-4,900
-43% -$23.9K ﹤0.01% 12594
2023
Q4 		$59.6K Buy
11,300
+4,800
+74% +$19K ﹤0.01% 11599
2023
Q3 		$21.4K Sell
6,500
-800
-11% -$2.81K ﹤0.01% 12575
2023
Q2 		$21.1K Buy
+7,300
New +$14K ﹤0.01% 12685
2023
Q1 		– Sell
-4,600
Closed -$12K – 14750
2022
Q4 		$12K Buy
+4,600
New +$20.1K ﹤0.01% 13534

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors's BVS Position: Q1 2026 in Review

Citadel Advisors reduced its Bioventus (BVS) stake by 72% in Q1 2026, selling an estimated $368K and leaving 17,085 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #11648.

Citadel Advisors first reported a position in BVS in Q2 2021 and has held it in 18 quarters since. The position peaked at $3.21M in Q3 2024. 157 funds tracked by Wall St. Rank hold BVS as of Q1 2026.

  • Citadel Advisors held 17,085 shares of Bioventus worth $156K as of Q1 2026.
  • Citadel Advisors sold 43,840 Bioventus shares in Q1 2026, an estimated $368K.
  • Bioventus made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11648 holding.
  • Citadel Advisors first reported a position in Bioventus in Q2 2021 and has held it in 18 quarters since.
  • Citadel Advisors's Bioventus position peaked at $3.21M in Q3 2024.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.